JP4467799B2 - ポリビニルアルコール微小球、ならびにその製造方法および治療用途 - Google Patents
ポリビニルアルコール微小球、ならびにその製造方法および治療用途 Download PDFInfo
- Publication number
- JP4467799B2 JP4467799B2 JP2000576829A JP2000576829A JP4467799B2 JP 4467799 B2 JP4467799 B2 JP 4467799B2 JP 2000576829 A JP2000576829 A JP 2000576829A JP 2000576829 A JP2000576829 A JP 2000576829A JP 4467799 B2 JP4467799 B2 JP 4467799B2
- Authority
- JP
- Japan
- Prior art keywords
- polyvinyl alcohol
- microsphere
- microspheres
- suspension
- embolization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920002451 polyvinyl alcohol Polymers 0.000 title claims abstract description 199
- 239000004372 Polyvinyl alcohol Substances 0.000 title claims abstract description 194
- 239000004005 microsphere Substances 0.000 title claims abstract description 162
- 238000004519 manufacturing process Methods 0.000 title claims description 25
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 193
- 238000000034 method Methods 0.000 claims abstract description 71
- 230000010102 embolization Effects 0.000 claims abstract description 59
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 238000013162 therapeutic embolization Methods 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000000725 suspension Substances 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 43
- 239000003921 oil Substances 0.000 claims description 36
- 235000019198 oils Nutrition 0.000 claims description 36
- 150000001299 aldehydes Chemical class 0.000 claims description 33
- 230000021164 cell adhesion Effects 0.000 claims description 32
- 239000012798 spherical particle Substances 0.000 claims description 29
- 238000003756 stirring Methods 0.000 claims description 29
- 239000000839 emulsion Substances 0.000 claims description 23
- 239000003550 marker Substances 0.000 claims description 23
- 229920002307 Dextran Polymers 0.000 claims description 22
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 230000001737 promoting effect Effects 0.000 claims description 18
- 239000000017 hydrogel Substances 0.000 claims description 16
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 14
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 125000003158 alcohol group Chemical group 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 208000032843 Hemorrhage Diseases 0.000 claims description 11
- 239000005662 Paraffin oil Substances 0.000 claims description 11
- 230000000740 bleeding effect Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 10
- 239000012216 imaging agent Substances 0.000 claims description 10
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000002872 contrast media Substances 0.000 claims description 8
- 239000000975 dye Substances 0.000 claims description 8
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 208000009443 Vascular Malformations Diseases 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 239000012454 non-polar solvent Substances 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- 239000003929 acidic solution Substances 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 102000004856 Lectins Human genes 0.000 claims description 5
- 108090001090 Lectins Proteins 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 150000001414 amino alcohols Chemical group 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000002523 lectin Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 229940015043 glyoxal Drugs 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010019633 Hepatic arteriovenous malformation Diseases 0.000 claims description 3
- 206010042220 Stress ulcer Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 230000003872 anastomosis Effects 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- KULQACNMKIDJNN-GASJEMHNSA-N (2r,3s,4r,5r)-1-aminohexane-1,2,3,4,5,6-hexol Chemical compound NC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO KULQACNMKIDJNN-GASJEMHNSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 206010052535 Small intestinal haemorrhage Diseases 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 206010067269 Uterine fibrosis Diseases 0.000 claims description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000026919 intracranial meningioma Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 2
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 2
- 239000001589 sorbitan tristearate Substances 0.000 claims description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 claims description 2
- 229960004129 sorbitan tristearate Drugs 0.000 claims description 2
- KUCOHFSKRZZVRO-UHFFFAOYSA-N terephthalaldehyde Chemical compound O=CC1=CC=C(C=O)C=C1 KUCOHFSKRZZVRO-UHFFFAOYSA-N 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 208000025421 tumor of uterus Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940102213 injectable suspension Drugs 0.000 abstract description 19
- 239000002245 particle Substances 0.000 description 55
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 230000001788 irregular Effects 0.000 description 9
- 208000034158 bleeding Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229960003433 thalidomide Drugs 0.000 description 6
- 239000002318 adhesion promoter Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XMPJICVFSDYOEG-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindole-1,3-dione Chemical compound O=C1C=2C(O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O XMPJICVFSDYOEG-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 3
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 230000005744 arteriovenous malformation Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011554 ferrofluid Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 101000686934 Mus musculus Prolactin-7D1 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 108010015046 cell aggregation factors Proteins 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- MZNMZWZGUGFQJP-UHFFFAOYSA-N 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCCCCCCC(O)CNCCCCCCCCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MZNMZWZGUGFQJP-UHFFFAOYSA-N 0.000 description 1
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229940123950 Prostaglandin synthase inhibitor Drugs 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940060237 akwa tears Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010104 catheter embolization Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Compounds Of Unknown Constitution (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/13019 | 1998-10-16 | ||
| FR9813019A FR2784580B1 (fr) | 1998-10-16 | 1998-10-16 | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
| PCT/EP1999/007846 WO2000023054A1 (en) | 1998-10-16 | 1999-10-15 | Polyvinyl alcohol microspheres, and methods for making and therapeutic uses of the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002527206A JP2002527206A (ja) | 2002-08-27 |
| JP2002527206A5 JP2002527206A5 (enExample) | 2008-06-05 |
| JP4467799B2 true JP4467799B2 (ja) | 2010-05-26 |
Family
ID=33462605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000576829A Expired - Lifetime JP4467799B2 (ja) | 1998-10-16 | 1999-10-15 | ポリビニルアルコール微小球、ならびにその製造方法および治療用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6680046B1 (enExample) |
| EP (1) | EP1128816B1 (enExample) |
| JP (1) | JP4467799B2 (enExample) |
| AT (1) | ATE262319T1 (enExample) |
| AU (1) | AU1039600A (enExample) |
| CA (1) | CA2345205A1 (enExample) |
| DE (1) | DE69915858T2 (enExample) |
| ES (1) | ES2219072T3 (enExample) |
| FR (1) | FR2784580B1 (enExample) |
| WO (1) | WO2000023054A1 (enExample) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
| FR2784580B1 (fr) * | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
| EP1163019B1 (en) * | 1999-03-25 | 2007-10-24 | Metabolix, Inc. | Medical devices and applications of polyhydroxyalkanoate polymers |
| EP1263325B1 (en) * | 2000-03-06 | 2009-07-01 | Boston Scientific Limited | Embolic agents visible under ultrasound |
| EP1263803B1 (en) * | 2000-03-13 | 2007-09-19 | BioCure, Inc. | Embolic compositions |
| US6652883B2 (en) | 2000-03-13 | 2003-11-25 | Biocure, Inc. | Tissue bulking and coating compositions |
| WO2001068722A1 (en) | 2000-03-13 | 2001-09-20 | Biocure, Inc. | Hydrogel biomedical articles |
| US6436424B1 (en) | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
| AU2001249221A1 (en) | 2000-03-20 | 2001-10-03 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
| US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
| EP1267839B1 (en) * | 2000-03-24 | 2007-10-03 | Biosphere Medical, Inc. | Microspheres for active embolization |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| US20040266983A1 (en) * | 2000-08-17 | 2004-12-30 | Reeve Lorraine E | Purified polyoxyalkylene block copolymers |
| US9080146B2 (en) * | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
| KR100786907B1 (ko) | 2001-09-12 | 2007-12-17 | 바이렉스 메디칼 코포레이션 | 고정화된 혈소판 결합제를 갖는 혈관 폐색 고형상 제제 |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7094369B2 (en) * | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7131997B2 (en) * | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| CA2492339A1 (en) * | 2002-06-12 | 2003-12-24 | Boston Scientific Limited | Bulking agents |
| US20080226723A1 (en) * | 2002-07-05 | 2008-09-18 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same |
| US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7588825B2 (en) * | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7883490B2 (en) * | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| CA2507404A1 (en) * | 2002-11-04 | 2004-05-21 | Biosphere Medical | Radioisotope-associated polymeric hydrogel microspheres and methods for producing and using the same |
| WO2004073688A1 (en) * | 2003-02-21 | 2004-09-02 | Biocompatibles Uk Limited | Drug delivery from embolic agents |
| CN1794980A (zh) * | 2003-03-24 | 2006-06-28 | 生物领域医疗公司 | 利用逆向热敏聚合物的暂时栓塞 |
| JP2004313759A (ja) * | 2003-03-31 | 2004-11-11 | Toray Ind Inc | 血管塞栓材料 |
| ES2819189T3 (es) | 2003-05-08 | 2021-04-15 | Tepha Inc | Tejidos y fibras médicos de polihidroxialcanoato |
| US20050025809A1 (en) * | 2003-07-08 | 2005-02-03 | Tepha, Inc. | Poly-4-hydroxybutyrate matrices for sustained drug delivery |
| WO2005020825A1 (en) * | 2003-08-22 | 2005-03-10 | Tepha, Inc. | Polyhydroxyalkanoate nerve regeneration devices |
| WO2005018600A2 (en) * | 2003-08-22 | 2005-03-03 | Cube Medical A/S | Method of treating a patient suffering from a solid tumour |
| US7976823B2 (en) * | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US7901770B2 (en) * | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7700086B2 (en) * | 2003-11-06 | 2010-04-20 | Pluromed, Inc. | Internal clamp for surgical procedures |
| US7736671B2 (en) * | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US20050238870A1 (en) * | 2004-04-22 | 2005-10-27 | Marcia Buiser | Embolization |
| JP4655505B2 (ja) * | 2004-04-28 | 2011-03-23 | 東レ株式会社 | 架橋生分解性粒子およびその製造方法 |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| WO2006004941A2 (en) | 2004-06-29 | 2006-01-12 | Biocure, Inc. | Biomaterial |
| EP2221069B1 (en) * | 2004-08-03 | 2012-05-09 | Tepha, Inc. | Non-curling polyhydroxyalkanoate sutures |
| US20070258939A1 (en) * | 2004-08-03 | 2007-11-08 | Biocamparibles Uk Limited | Drug Delivery from Embolic Agents |
| US20070281028A1 (en) * | 2004-08-04 | 2007-12-06 | Biocompatibles Uk Limited | Drug Delivery of a Cox Inhibitor from Embolic Agents |
| US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
| KR101153785B1 (ko) | 2004-10-25 | 2012-07-09 | 셀로노바 바이오사이언시스 저머니 게엠베하 | 치료 및/또는 진단용으로 부가할 수 있는 중합체 입자 및이의 제조 및 사용 방법 |
| US9114162B2 (en) * | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
| US9107850B2 (en) * | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| US8663225B2 (en) * | 2004-11-12 | 2014-03-04 | Medtronic, Inc. | Hydrogel bone void filler |
| US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7727555B2 (en) * | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7858183B2 (en) * | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7963287B2 (en) * | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| MX2007013914A (es) | 2005-05-09 | 2008-02-22 | Biosphere Medical S A | Composiciones y metodos que usan microesferas y agentes de contraste no ionicos. |
| US20070004973A1 (en) * | 2005-06-15 | 2007-01-04 | Tan Sharon M L | Tissue treatment methods |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| EP1900381A4 (en) | 2005-07-01 | 2012-01-11 | Nippon Synthetic Chem Ind | PVA PARTICLES FOR THE USE IN THE TEMPORARY EMBOLIZATION OF A BLOOD VESSEL, METHOD OF MANUFACTURING THEREOF AND ACTIVE FOR THE TEMPORARY EMBOLIZATION OF A BLOOD VESSEL |
| US20070083219A1 (en) * | 2005-10-12 | 2007-04-12 | Buiser Marcia S | Embolic coil introducer sheath locking mechanisms |
| US8007509B2 (en) * | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
| US20070093907A1 (en) * | 2005-10-26 | 2007-04-26 | Goupil Dennis W | Hydrogel spinal disc implants with swellable articles |
| US8152839B2 (en) * | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
| US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
| US20070142859A1 (en) * | 2005-12-19 | 2007-06-21 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7501179B2 (en) * | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US7947368B2 (en) * | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US20070142560A1 (en) * | 2005-12-21 | 2007-06-21 | Young-Ho Song | Block copolymer particles |
| JP5075130B2 (ja) * | 2006-01-24 | 2012-11-14 | バイオコンパティブルズ ユーケー リミテッド | ポリマー粒子を薬物で負荷する方法 |
| EP1986707A2 (en) * | 2006-01-30 | 2008-11-05 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
| WO2007090130A2 (en) * | 2006-01-30 | 2007-08-09 | Surgica Corporation | Porous intravascular embolization particles and related methods |
| US7838035B2 (en) | 2006-04-11 | 2010-11-23 | E. I. Du Pont De Nemours And Company | Microsphere powder of high density, swellable, deformable, durable occlusion-forming microspheres |
| US8062673B2 (en) | 2006-04-11 | 2011-11-22 | E I Du Pont De Nemours And Company | Process for embolization using swellable and deformable microspheres |
| US8252339B2 (en) | 2006-04-11 | 2012-08-28 | Massachusetts Institute Of Technology | Medical treatment applications of swellable and deformable microspheres |
| US7794755B2 (en) | 2006-04-11 | 2010-09-14 | E.I. Du Pont De Nemours And Company | Process for preparation of swellable and deformable microspheres |
| US20070299461A1 (en) * | 2006-06-21 | 2007-12-27 | Boston Scientific Scimed, Inc. | Embolic coils and related components, systems, and methods |
| WO2008014065A1 (en) * | 2006-07-27 | 2008-01-31 | Boston Scientific Limited | Particles |
| US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
| US7943683B2 (en) * | 2006-12-01 | 2011-05-17 | Tepha, Inc. | Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers |
| US20080145658A1 (en) * | 2006-12-15 | 2008-06-19 | Boston Scientific Scimed, Inc. | Freeze Thaw Methods For Making Polymer Particles |
| WO2009046281A2 (en) * | 2007-10-05 | 2009-04-09 | Boston Scientific Scimed, Inc. | Injectable particles |
| US20090110738A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same |
| US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
| US20090110730A1 (en) * | 2007-10-30 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same |
| US20090110731A1 (en) * | 2007-10-30 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same |
| US8114436B2 (en) | 2008-03-25 | 2012-02-14 | Boston Scientific Scimed, Inc. | Compositions and methods for delivery of embolics |
| CN102143996A (zh) * | 2008-10-30 | 2011-08-03 | 大卫·刘 | 微球形多孔可生物相容支架及制造该支架的方法和装置 |
| KR101386799B1 (ko) * | 2009-10-06 | 2014-04-21 | 리전츠 오브 더 유니버스티 오브 미네소타 | 생분해성 색전술용 미소구체 |
| WO2011057131A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
| JP2013509963A (ja) | 2009-11-09 | 2013-03-21 | スポットライト テクノロジー パートナーズ エルエルシー | 断片化ヒドロゲル |
| GB201008843D0 (en) * | 2010-05-27 | 2010-07-14 | Aubin Ltd | Method and composition |
| US9232805B2 (en) | 2010-06-29 | 2016-01-12 | Biocure, Inc. | In-situ forming hydrogel wound dressings containing antimicrobial agents |
| CN101885852B (zh) * | 2010-07-07 | 2012-01-11 | 天津大学 | 表面光滑明胶微球与制备方法 |
| WO2012050879A2 (en) * | 2010-09-29 | 2012-04-19 | Scion Cardio-Vascular, Inc. | Methods for processing microspheres, microspheres processed thereby, and uses thereof |
| EP2646000B1 (en) | 2010-11-29 | 2015-04-29 | Centre Hospitalier Universitaire Vaudois | Chemoembolization composition comprising anti-angiogenic agents |
| GB201101429D0 (en) * | 2011-01-27 | 2011-03-16 | Biocompatibles Uk Ltd | Drug delivery system |
| IT1404015B1 (it) * | 2011-02-04 | 2013-11-08 | Hsd Holding Smart Device S R L | Uso di un polimero di destrano reticolato come filtro contro l'inalazione di sostanze nocive per la salute |
| CN102492178B (zh) * | 2011-11-29 | 2014-12-24 | 中国科学院过程工程研究所 | 一种尺寸均一的魔芋葡甘聚糖微球及其制备方法 |
| EP3984556B8 (en) | 2012-06-14 | 2025-07-09 | Microvention, Inc. | Polymeric treatment compositions |
| CN104717983B (zh) | 2012-10-15 | 2018-09-18 | 微仙美国有限公司 | 聚合治疗组合物 |
| US8936795B2 (en) | 2012-12-19 | 2015-01-20 | Regents Of The University Of Minnesota | Liquid embolic material including carboxymethyl chitosan crosslinked with carboxymethyl cellulose |
| EP2968165B1 (en) | 2013-03-13 | 2023-09-13 | Biosphere Medical, Inc. | Compositions and associated methods for radioisotope-binding microparticles |
| GB2519738A (en) * | 2013-09-06 | 2015-05-06 | Biocompatibles Uk Ltd | Radiopaque polymers |
| US9408916B2 (en) | 2013-09-19 | 2016-08-09 | Microvention, Inc. | Polymer films |
| EP3046952B1 (en) | 2013-09-19 | 2021-05-12 | Terumo Corporation | Polymer particles |
| US9688788B2 (en) | 2013-11-08 | 2017-06-27 | Terumo Corporation | Polymer particles |
| US10500303B2 (en) | 2014-08-15 | 2019-12-10 | Tepha, Inc. | Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof |
| CA2969429C (en) | 2014-12-11 | 2020-10-27 | Tepha, Inc. | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof |
| US10626521B2 (en) | 2014-12-11 | 2020-04-21 | Tepha, Inc. | Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof |
| WO2016154592A1 (en) | 2015-03-26 | 2016-09-29 | Microvention, Inc. | Embiolic particles |
| US10071181B1 (en) | 2015-04-17 | 2018-09-11 | Teleflex Innovations S.À.R.L. | Resorbable embolization spheres |
| US10517910B2 (en) * | 2015-06-19 | 2019-12-31 | Sillajen, Inc. | Compositions and methods for viral embolization |
| CN105148327B (zh) * | 2015-07-29 | 2019-07-12 | 广东博与再生医学有限公司 | 一种多糖-聚乙烯醇栓塞微球的制备方法 |
| US10182979B2 (en) | 2016-03-22 | 2019-01-22 | Regents Of The University Of Minnesota | Biodegradable microspheres |
| JP2019518428A (ja) * | 2016-04-12 | 2019-07-04 | ユニシテ エーファウ アクチェンゲゼルシャフト | 体液試料からの細胞外小胞（ｅｖ）の単離 |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| KR102162370B1 (ko) | 2016-09-28 | 2020-10-06 | 테루모 가부시키가이샤 | 중합체 입자 |
| EA038657B1 (ru) * | 2016-10-12 | 2021-09-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Химиоэмболизирующие частицы для лечения солидных опухолей |
| CN111200976B (zh) | 2017-10-09 | 2023-07-07 | 微仙美国有限公司 | 放射性液体栓塞 |
| CN108744020A (zh) * | 2018-06-12 | 2018-11-06 | 杭州艾力康医药科技有限公司 | 一种离子交换型聚乙烯醇微球的制备方法 |
| US12043706B2 (en) | 2018-11-21 | 2024-07-23 | Kuraray Co., Ltd. | Monodisperse hydrogel particles |
| JP2023507044A (ja) * | 2019-06-19 | 2023-02-20 | ザイロ セラピューティクス，インコーポレーテッド | 医薬品および化粧用途のための一酸化窒素担体としての硫黄官能化モノリスおよびそれに由来する粒子 |
| JPWO2021166746A1 (enExample) * | 2020-02-18 | 2021-08-26 | ||
| CN114159554B (zh) * | 2021-11-22 | 2022-12-13 | 广州优理氏生物科技有限公司 | 一种纤连蛋白-聚乙烯醇微球的制备方法及其应用 |
| CN114642640B (zh) * | 2022-05-23 | 2022-09-16 | 杭州旸顺医疗科技有限公司 | 微球及其制备方法、制备系统 |
| CN120769874A (zh) | 2023-02-22 | 2025-10-10 | 株式会社可乐丽 | 干燥水凝胶形成性物品、水凝胶、和干燥水凝胶形成性物品的制造方法 |
| WO2024182477A2 (en) * | 2023-02-28 | 2024-09-06 | Medstar Health, Inc. | Angiogenesis inhibitors coupled to embolic microparticles |
| CN116159178B (zh) * | 2023-04-18 | 2023-07-04 | 上海汇禾医疗器械有限公司 | 一种小粒径栓塞微球及其制备方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US499188A (en) * | 1893-06-06 | Territory | ||
| US3919411A (en) | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
| JPS49108168A (enExample) | 1973-02-16 | 1974-10-15 | ||
| JPS49108158A (enExample) | 1973-02-19 | 1974-10-15 | ||
| JPS5350290A (en) | 1976-10-18 | 1978-05-08 | Sumitomo Chem Co Ltd | Preparation f hydrogel |
| CA1134977A (en) * | 1978-09-07 | 1982-11-02 | Sumitomo Chemical Co., Ltd. | Method for preparing highly absorbent polymers |
| US4314032A (en) * | 1978-10-26 | 1982-02-02 | Kureha Kagaku Kogyo Kabushiki Kaisha | Crosslinked polyvinyl alcohol gel |
| US4268495A (en) | 1979-01-08 | 1981-05-19 | Ethicon, Inc. | Injectable embolization and occlusion solution |
| US4306031A (en) * | 1979-08-14 | 1981-12-15 | Mitsubishi Chemical Industries Limited | Weakly acidic cation exchange resin and process for producing same |
| GB2088392B (en) * | 1980-12-03 | 1984-05-02 | Sumitomo Chemical Co | Production of hydrogels |
| JPS57128709A (en) | 1981-02-03 | 1982-08-10 | Sumitomo Chem Co Ltd | Preparation of hydrogel |
| CA1225585A (en) | 1983-06-30 | 1987-08-18 | Maria T. Litvinova | Composition for embolization of blood vessels |
| GB8418772D0 (en) | 1984-07-24 | 1984-08-30 | Geistlich Soehne Ag | Chemical substances |
| US5186922A (en) * | 1985-03-15 | 1993-02-16 | See/Shell Biotechnology, Inc. | Use of biodegradable microspheres labeled with imaging energy constrast materials |
| US4680171A (en) * | 1985-03-15 | 1987-07-14 | William Shell | Visualization of a bloodstream circulation with biodegradable microspheres |
| WO1987000062A1 (en) | 1985-07-02 | 1987-01-15 | Target Therapeutics | Vaso-occlusive collagen composition and method |
| US4803075A (en) | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| JPS6317904A (ja) * | 1986-07-09 | 1988-01-25 | Mitsubishi Chem Ind Ltd | 多孔質架橋ポリビニルアルコ−ル粒子の製造法 |
| CA1329800C (en) * | 1987-12-29 | 1994-05-24 | Hiroaki Takayanagi | Composite separating agent |
| GB8813425D0 (en) | 1988-06-07 | 1988-07-13 | Hall L D | Magnetic resonance imaging |
| JPH064713B2 (ja) * | 1988-07-22 | 1994-01-19 | テルモ株式会社 | 生体適合性材料 |
| JPH0286838A (ja) * | 1988-09-22 | 1990-03-27 | Terumo Corp | 水不溶性ヒドロゲルおよびその製造方法 |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US5258028A (en) | 1988-12-12 | 1993-11-02 | Ersek Robert A | Textured micro implants |
| US5092883A (en) | 1988-12-28 | 1992-03-03 | Eppley Barry L | Method for promoting soft connective tissue growth and repair in mammals |
| GB8900376D0 (en) * | 1989-01-09 | 1989-03-08 | Nycomed As | Iodinated esters |
| US5007940A (en) | 1989-06-09 | 1991-04-16 | American Medical Systems, Inc. | Injectable polymeric bodies |
| DE69114782T2 (de) * | 1990-08-08 | 1996-04-18 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff. |
| US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| JPH06505991A (ja) * | 1991-02-25 | 1994-07-07 | デビオファルム ソシエテ アノニム | 癌の多剤耐性を抑制するための薬剤 |
| FR2676927B1 (fr) | 1991-05-29 | 1995-06-23 | Ibf | Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant. |
| JP3356447B2 (ja) * | 1991-10-16 | 2002-12-16 | テルモ株式会社 | 乾燥高分子ゲルからなる血管病変塞栓材料 |
| NZ249770A (en) * | 1992-02-28 | 1996-09-25 | Univ Texas | Biodegradable, polymerisable, substantially water soluble macromer comprising at least one water soluble region, at least one degradable region and at least two free radical polymerisable regions separated by at least one degradable region |
| JPH0656676A (ja) | 1992-08-05 | 1994-03-01 | Hori Shinichi | 血管塞栓用懸濁液 |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| EP0688429B1 (en) | 1993-03-09 | 1998-02-11 | Epic Therapeutics, Inc.. | Macromolecular microparticles and methods of production |
| UA10911C2 (uk) | 1994-08-10 | 1996-12-25 | Мале Впроваджувальне Підприємство "Іhтерфалл" | Біосумісhий гідрогель |
| US5955108A (en) | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
| WO1996022736A1 (en) * | 1995-01-27 | 1996-08-01 | Scimed Life Systems, Inc. | Embolizing system |
| US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| DE19601699A1 (de) * | 1996-01-18 | 1997-07-24 | Wacker Chemie Gmbh | Redispergierbare Polymerisatpulver und daraus erhältliche wäßrige Polymerisat-Dispersionen |
| US5785977A (en) | 1996-02-07 | 1998-07-28 | Breithbarth; Richard | Non-metallic microparticle carrier materials |
| US5803075A (en) * | 1996-03-15 | 1998-09-08 | Yaru Llc | Surgical mask with adhesive strip to improve breathing |
| US5925683A (en) * | 1996-10-17 | 1999-07-20 | Target Therapeutics, Inc. | Liquid embolic agents |
| US6139963A (en) * | 1996-11-28 | 2000-10-31 | Kuraray Co., Ltd. | Polyvinyl alcohol hydrogel and process for producing the same |
| WO1999011196A1 (en) | 1997-09-04 | 1999-03-11 | Point Biomedical Corporation | Injectable tissue reconstruction material |
| WO1999012577A1 (en) * | 1997-09-05 | 1999-03-18 | Nycomed Imaging As | Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
| AU742786B2 (en) | 1998-03-06 | 2002-01-10 | Biosphere Medical, Inc. | Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
| US6165193A (en) * | 1998-07-06 | 2000-12-26 | Microvention, Inc. | Vascular embolization with an expansible implant |
| FR2784580B1 (fr) | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
| US6710126B1 (en) * | 1999-11-15 | 2004-03-23 | Bio Cure, Inc. | Degradable poly(vinyl alcohol) hydrogels |
| KR100335866B1 (ko) * | 2000-01-06 | 2002-05-10 | 박호군 | 폴리아세트산비닐 코어/폴리비닐알코올 외피의 2중 구조를갖는 미세구형 색전재료 및 그의 제조방법 |
| EP1263803B1 (en) * | 2000-03-13 | 2007-09-19 | BioCure, Inc. | Embolic compositions |
| US6652883B2 (en) * | 2000-03-13 | 2003-11-25 | Biocure, Inc. | Tissue bulking and coating compositions |
| AU2001249221A1 (en) | 2000-03-20 | 2001-10-03 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
| US6436424B1 (en) | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
| US7338657B2 (en) | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
| EP1267839B1 (en) | 2000-03-24 | 2007-10-03 | Biosphere Medical, Inc. | Microspheres for active embolization |
| US20030212022A1 (en) | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| US6537569B2 (en) * | 2001-02-14 | 2003-03-25 | Microvention, Inc. | Radiation cross-linked hydrogels |
| WO2002100444A1 (en) | 2001-06-08 | 2002-12-19 | Biosphere Medical Inc. | Colloidal metal labelled microparticles, their production and use |
| US6488952B1 (en) * | 2001-08-28 | 2002-12-03 | John P. Kennedy | Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system |
| US6911219B2 (en) | 2001-09-27 | 2005-06-28 | Surgica Corporation | Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them |
| MX2007013914A (es) | 2005-05-09 | 2008-02-22 | Biosphere Medical S A | Composiciones y metodos que usan microesferas y agentes de contraste no ionicos. |
| EP1986707A2 (en) | 2006-01-30 | 2008-11-05 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
| WO2007090130A2 (en) | 2006-01-30 | 2007-08-09 | Surgica Corporation | Porous intravascular embolization particles and related methods |
-
1998
- 1998-10-16 FR FR9813019A patent/FR2784580B1/fr not_active Expired - Fee Related
-
1999
- 1999-10-15 DE DE69915858T patent/DE69915858T2/de not_active Expired - Lifetime
- 1999-10-15 AU AU10396/00A patent/AU1039600A/en not_active Abandoned
- 1999-10-15 WO PCT/EP1999/007846 patent/WO2000023054A1/en not_active Ceased
- 1999-10-15 US US09/419,114 patent/US6680046B1/en not_active Expired - Lifetime
- 1999-10-15 JP JP2000576829A patent/JP4467799B2/ja not_active Expired - Lifetime
- 1999-10-15 ES ES99953858T patent/ES2219072T3/es not_active Expired - Lifetime
- 1999-10-15 CA CA002345205A patent/CA2345205A1/en not_active Abandoned
- 1999-10-15 AT AT99953858T patent/ATE262319T1/de not_active IP Right Cessation
- 1999-10-15 EP EP99953858A patent/EP1128816B1/en not_active Revoked
-
2003
- 2003-10-27 US US10/692,785 patent/US7591993B2/en not_active Expired - Fee Related
-
2009
- 2009-01-05 US US12/348,867 patent/US7670592B2/en not_active Expired - Fee Related
-
2010
- 2010-01-12 US US12/686,320 patent/US8673266B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69915858T2 (de) | 2005-03-03 |
| US6680046B1 (en) | 2004-01-20 |
| DE69915858D1 (de) | 2004-04-29 |
| US20090117196A1 (en) | 2009-05-07 |
| US8673266B2 (en) | 2014-03-18 |
| CA2345205A1 (en) | 2000-04-27 |
| WO2000023054A1 (en) | 2000-04-27 |
| US20040091425A1 (en) | 2004-05-13 |
| AU1039600A (en) | 2000-05-08 |
| US7670592B2 (en) | 2010-03-02 |
| ATE262319T1 (de) | 2004-04-15 |
| FR2784580A1 (fr) | 2000-04-21 |
| FR2784580B1 (fr) | 2004-06-25 |
| EP1128816A1 (en) | 2001-09-05 |
| US20100119572A1 (en) | 2010-05-13 |
| ES2219072T3 (es) | 2004-11-16 |
| JP2002527206A (ja) | 2002-08-27 |
| US7591993B2 (en) | 2009-09-22 |
| EP1128816B1 (en) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4467799B2 (ja) | ポリビニルアルコール微小球、ならびにその製造方法および治療用途 | |
| US8173176B2 (en) | Embolization | |
| US8865221B2 (en) | Swellable and degradable microspheres | |
| US6602524B2 (en) | Microspheres for use in the treatment of cancer | |
| JP4895802B2 (ja) | 固形腫瘍の化学的塞栓療法用組成物 | |
| JP2001509133A (ja) | 閉塞化血管における使用のための組成物 | |
| JP2002519364A (ja) | 乳酸エチルを含有する血管塞栓形成組成物及びその使用方法 | |
| JP6280996B2 (ja) | 治療剤の放出を伴う急速分解性塞栓粒子および同塞栓粒子を含む医療用組成物 | |
| JP3879018B2 (ja) | 生体適合性物質の水不溶化多孔性粒子及びその製造法 | |
| JPWO1998003203A1 (ja) | 生体適合性物質の水不溶化多孔性粒子及びその製造法 | |
| CN110527007A (zh) | 聚（2-氰基丙烯酸）及其制备方法和应用 | |
| JP2005112858A (ja) | 生体適合性物質の水不溶化多孔性粒子及びその製造法 | |
| JP2005103319A (ja) | 生体適合性物質の水不溶化多孔性粒子及びその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051005 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090714 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091001 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100209 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4467799 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140305 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |